Regeneron: Antibody Cocktail 100 Percent Effective Against Symptomatic COVID-19 Infections

Eli Lilly also reported positive results for neutralizing antibody treatment

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, on Sept. 17, 2020. Brendan McDermid/Reuters

Regeneron Pharmaceuticals on Tuesday announced that a phase 3 trial still in progress of an antibody cocktail has shown a 100 percent prevention of symptomatic COVID-19 infections.

Interim results also show approximately 50 percent lower overall rates of infection across all patients.